Illumina announced the launch of the next generation of TruSight Oncology 500 (TSO 500 v2), its flagship cancer research assay for comprehensive genomic profiling (CGP).

CGP helps labs identify molecular tumor profiles to support research in therapy selection and clinical trial eligibility. The new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements.

“TSO 500 is trusted by researchers worldwide. With this update, we deliver more value through HRD detection, faster results, and less sample use,” said Everett Cunningham, Chief Commercial Officer at Illumina. “Complete workflow solutions like this can expand access to tumor profiling and advance cancer therapy research.”

From a small tissue sample, TSO 500 v2 analyzes hundreds of genes across all variant classes and immuno-oncology biomarkers. Studies show that using CGP early in a cancer diagnosis can lead to more personalized treatment and better outcomes.

TSO 500 v2 now includes homologous recombination deficiency (HRD) analysis for all samples at no extra cost. The HRD status is calculated using the Genomic Instability Score (GIS) algorithm licensed from Myriad Genetics, allowing broader research on HRD as a cancer biomarker.

 Dr. Weiyi Chen, Technical Director at siParadigm Diagnostic Informatics, said: “We saw better data accuracy with TSO 500 v2 compared to our current vendor. The workflow is faster and includes HRD analysis. Turnaround time matters to us, and this solution also helps cut service costs by consolidating testing on Illumina sequencers.”